{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:40:19Z","timestamp":1792424419099,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Channel 7 Children\u2019s Research Foundation","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"name":"Future Making Fellowship","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Genetic therapies offer a promising strategy for treating cystic fibrosis (CF) lung disease, particularly for individuals with modulator-ineligible genotypes. However, clinical translation has been slower than anticipated. While CF gene therapy candidates typically demonstrate high efficacy in preclinical studies, all products trialled to date have failed to progress beyond Phase I\/II, raising questions about the predictive capacity of current preclinical models. One contributing factor may be the absence of severe muco-obstructive lung disease in commonly used CF rodent models, highlighting the need to evaluate gene vectors under conditions that more closely recapitulate the CF lung environment. In this study, we evaluated a vesicular stomatitis virus glycoprotein G (VSV-G) pseudotyped lentiviral (LV) vector carrying the\n                    <jats:italic>luciferase<\/jats:italic>\n                    reporter gene under conditions of\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    lung infection in wild-type and CF rats. Bioluminescence imaging was conducted on days 7 and 14 post-LV vector administration to assess lung transgene expression under infected and non-infected conditions. At day 7, there was no significant difference in bioluminescence between\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    -infected and non-infected animals (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.537). From day 7 to day 14, bioluminescence decreased 136-fold in non-infected animals (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001), compared with a 7-fold decrease in infected animals (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.043), with a significant infection \u00d7 time interaction indicating that the magnitude of decline was greater in non-infected controls (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.024). These findings demonstrate that lung disease state can modulate transgene expression and persistence, highlighting the importance of evaluating gene therapy vectors under conditions that more closely mimic the CF lung environment.\n                  <\/jats:p>","DOI":"10.1038\/s41434-026-00652-y","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:58:01Z","timestamp":1792421881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic lung infection does not impair lentiviral vector gene transfer in a cystic fibrosis rat model"],"prefix":"10.1038","author":[{"given":"Alexandra","family":"McCarron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Reyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Boog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cmielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Donnelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"652_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4187\/respcare.06697","volume":"65","author":"NL Turcios","year":"2020","unstructured":"Turcios NL. Cystic fibrosis lung disease: an overview. Respir Care. 2020;65:233\u201351.","journal-title":"Respir Care"},{"key":"652_CR2","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2019","unstructured":"Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharm. 2019;10:1662.","journal-title":"Front Pharm"},{"key":"652_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241297877","volume":"18","author":"L Somerville","year":"2024","unstructured":"Somerville L, Borish L, Noth I, Albon D. Modulator-refractory cystic fibrosis: defining the scope and challenges of an emerging at-risk population. Ther Adv Respir Dis. 2024;18:17534666241297877.","journal-title":"Ther Adv Respir Dis"},{"key":"652_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:53.","journal-title":"Signal Transduct Target Ther"},{"key":"652_CR5","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/14712598.2020.1787981","volume":"20","author":"AM Munis","year":"2020","unstructured":"Munis AM, Bentley EM, Takeuchi Y. A tool with many applications: vesicular stomatitis virus in research and medicine. Expert Opin Biol Ther. 2020;20:1187\u2013201.","journal-title":"Expert Opin Biol Ther"},{"key":"652_CR6","doi-asserted-by":"crossref","unstructured":"Sinn PL, Cooney AL, Oakland M, Dylla DE, Wallen TJ, Pezzulo AA, et al. Lentiviral vector gene transfer to porcine airways. Mol Ther Nucleic Acids. 2012;1:e56.","DOI":"10.1038\/mtna.2012.47"},{"key":"652_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41434-022-00332-7","volume":"30","author":"A McCarron","year":"2023","unstructured":"McCarron A, Cmielewski P, Drysdale V, Parsons D, Donnelley M. Effective viral-mediated lung gene therapy: is airway surface preparation necessary? Gene Ther. 2023;30:469\u201377.","journal-title":"Gene Ther"},{"key":"652_CR8","doi-asserted-by":"crossref","unstructured":"Munir M, Wiyana J, Werder RB, Butcher NJ, Burow R, McCarron A, et al. Predicting clinical efficacy of lung gene delivery in people with cystic fibrosis: which in vitro and in vivo models best predict outcomes in human lungs? Expert Opin Drug Deliv. 2026;23:1531\u201349.","DOI":"10.1080\/17425247.2026.2684641"},{"key":"652_CR9","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397:2195\u2013211.","journal-title":"Lancet"},{"key":"652_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","volume":"37","author":"Z Pang","year":"2019","unstructured":"Pang Z, Raudonis R, Glick BR, Lin T-J, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37:177\u201392.","journal-title":"Biotechnol Adv"},{"key":"652_CR11","doi-asserted-by":"publisher","first-page":"538.","DOI":"10.3390\/genes9110538","volume":"9","author":"AL Cooney","year":"2018","unstructured":"Cooney AL, McCray PB, Sinn PL. Cystic fibrosis gene therapy: looking back, looking forward. Genes. 2018;9:538.","journal-title":"Genes"},{"key":"652_CR12","doi-asserted-by":"publisher","first-page":"e19919","DOI":"10.1371\/journal.pone.0019919","volume":"6","author":"K Hida","year":"2011","unstructured":"Hida K, Lai SK, Suk JS, Won SY, Boyle MP, Hanes J. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PLoS One. 2011;6:e19919.","journal-title":"PLoS One"},{"key":"652_CR13","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/mt.2014.89","volume":"22","author":"BS Schuster","year":"2014","unstructured":"Schuster BS, Kim AJ, Kays JC, Kanzawa MM, Guggino WB, Boyle MP, et al. Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Mol Ther. 2014;22:1484\u201393.","journal-title":"Mol Ther"},{"key":"652_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/sj.gt.3300593","volume":"5","author":"A van Heeckeren","year":"1998","unstructured":"van Heeckeren A, Ferkol T, Tosi M. Effects of bronchopulmonary inflammation induced by Pseudomonas aeruginosa on adenovirus-mediated gene transfer to airway epithelial cells in mice. Gene Ther. 1998;5:345\u201351.","journal-title":"Gene Ther"},{"key":"652_CR15","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1089\/hum.2014.002","volume":"25","author":"M Myint","year":"2014","unstructured":"Myint M, Limberis MP, Bell P, Somanathan S, Haczku A, Wilson JM, et al. In vivo evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection. Hum Gene Ther. 2014;25:966\u201376.","journal-title":"Hum Gene Ther"},{"key":"652_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/hum.2009.085","volume":"21","author":"J Rejman","year":"2009","unstructured":"Rejman J, De Fino I, Paroni M, Bragonzi A, Demeester J, De Smedt S, et al. Impact of chronic pulmonary infection with Pseudomonas aeruginosa on transfection mediated by viral and nonviral vectors. Hum Gene Ther. 2009;21:351\u20136.","journal-title":"Hum Gene Ther"},{"key":"652_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.ajpath.2020.01.009","volume":"190","author":"A McCarron","year":"2020","unstructured":"McCarron A, Cmielewski P, Reyne N, McIntyre C, Finnie J, Craig F, et al. Phenotypic characterization and comparison of cystic fibrosis rat models generated using CRISPR\/Cas9 gene editing. Am J Pathol. 2020;190:977\u201393.","journal-title":"Am J Pathol"},{"key":"652_CR18","doi-asserted-by":"crossref","unstructured":"Reyne N, Boog B, Cmielewski P, McCarron A, Smith R, Rout-Pitt N, et al. A longitudinal evaluation of localised chronic Pseudomonas aeruginosa infection in cystic fibrosis rat models. BMC Microbiol. 2026;26:368.","DOI":"10.1186\/s12866-026-04893-0"},{"key":"652_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/01902148.2021.1989523","volume":"47","author":"N Rout-Pitt","year":"2021","unstructured":"Rout-Pitt N, Donnelley M, Parsons D. In vitro optimization of miniature bronchoscope lentiviral vector delivery for the small animal lung. Exp Lung Res. 2021;47:417\u201325.","journal-title":"Exp Lung Res"},{"key":"652_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1465-9921-11-84","volume":"11","author":"P Cmielewski","year":"2010","unstructured":"Cmielewski P, Anson DS, Parsons DW. Lysophosphatidylcholine as an adjuvant for lentiviral vector-mediated gene transfer to airway epithelium: effect of acyl chain length. Respir Res. 2010;11:84.","journal-title":"Respir Res"},{"key":"652_CR21","doi-asserted-by":"publisher","first-page":"669635","DOI":"10.3389\/fphar.2021.669635","volume":"12","author":"A McCarron","year":"2021","unstructured":"McCarron A, Farrow N, Cmielewski P, Knight E, Donnelley M, Parsons D. Breaching the delivery barrier: chemical and physical airway epithelium disruption strategies for enhancing lentiviral-mediated gene therapy. Front Pharm. 2021;12:669635.","journal-title":"Front Pharm"},{"key":"652_CR22","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1089\/hum.2022.086","volume":"33","author":"V Drysdale","year":"2022","unstructured":"Drysdale V, Cmielewski P, Donnelley M, Reyne N, Parsons D, McCarron A. Comparison of physical perturbation devices for enhancing lentiviral vector-mediated gene transfer to the airway epithelium. Hum Gene Ther. 2022;33:1062\u201372.","journal-title":"Hum Gene Ther"},{"key":"652_CR23","doi-asserted-by":"crossref","unstructured":"Malhotra S, Hayes D, Jr., Wozniak DJ. Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clin Microbiol Rev. 2019;32:e00138\u201318.","DOI":"10.1128\/CMR.00138-18"},{"key":"652_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jcf.2020.10.008","volume":"20","author":"L Jackson","year":"2021","unstructured":"Jackson L, Waters V. Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros. 2021;20:8\u201316.","journal-title":"J Cyst Fibros"},{"key":"652_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00018-016-2387-7","volume":"74","author":"CM Farinha","year":"2017","unstructured":"Farinha CM, Canato S. From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking. Cell Mol Life Sci. 2017;74:39\u201355.","journal-title":"Cell Mol Life Sci"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00652-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00652-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00652-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:58:03Z","timestamp":1792421883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00652-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":25,"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00652-y","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Animal work was conducted with approval from the Adelaide University Animal Ethics Committee (M-2023-011). All procedures were performed in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declaration"}}]}}